3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gynecologic
2
Thoracic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Prostatic Neoplasms
7
Wilms Tumor
1
Testicular Germ Cell Tumor
1
Prostate Cancer Metastatic
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic cancer, adult
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Kidney Neoplasms
1
Hepatic Veno-Occlusive Disease
1
Glioblastoma
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
36
Carboplatin
28
Paclitaxel
23
Filgrastim
17
Nivolumab
14
Gemcitabine
14
Cyclophosphamide
14
Ifosfamide
13
Cisplatin
13
Docetaxel
12
Specimen Handling
11
Etoposide
11
olaparib
9
Peripheral Blood Stem Cell Transplantation
9
Magnetic Resonance Spectroscopy
8
fludarabine
6
Temozolomide
6
Ipilimumab
6
Fluorouracil
6
Biopsy
6
Albumin-Bound Paclitaxel
6
rucaparib
5
avelumab
5
atezolizumab
5
Trastuzumab
5
Thiotepa
5
Taxes
5
Standard of Care
5
palbociclib
4
durvalumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Hematologic Tests
×
Genitourinary
×
Clear all
NCT06717295
2026-01-02
CCANED-CIPHER
Dysplasia Diagnostics Limited
Recruiting
6,000 enrolled